RxDoctor Payments Data

Adrian Ma, MD

Cardiovascular Disease · San Jose, CANPI 1952305971

Payments from drug & device makers

$4,262in general payments, 2019–2025

Across 95 payments — averaging $44.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • E.r. Squibb & Sons, L.L.C.$554
  • AstraZeneca$339
  • Ablative Solutions, Inc.$251
  • Janssen Scientific Affairs, LLC$240
  • Novo Nordisk$237
  • plus $1K from 12 others

What the payments were for

  • Grants$1233%
  • Travel & lodging$72917%
  • Food & beverage$3,12873%
  • Education$2827%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)14$1,352
E.r. Squibb & Sons, L.L.C.21$554
AstraZeneca6$339
Ablative Solutions, Inc.2$251
Janssen Scientific Affairs, LLC2$240
Novo Nordisk2$237
Boehringer Ingelheim28$198
Edwards Lifesciences1$153
Amgen1$149
Pfizer3$148
Merck2$141
Bayer2$139
Amarin Pharma, Inc.4$118
Intuitive Surgical1$95
Johnson & Johnson2$56
Novartis2$50
Abbott1$28
Medicomp Inc1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,262 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,254,237
Medicare patients
568
Services billed
6,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban751$761,202
XareltoRivaroxaban181$205,612
EntrestoSacubitril/Valsartan145$148,349
JardianceEmpagliflozin100$94,076
MultaqDronedarone Hcl39$60,729
FarxigaDapagliflozin Propanediol48$39,507
BrilintaTicagrelor33$18,433
VerquvoVericiguat17$14,951
VascepaIcosapent Ethyl19$14,371
Repatha SureclickEvolocumab25$13,461
Metoprolol Succinate571$7,338
Praluent PenAlirocumab13$6,429
PradaxaDabigatran Etexilate Mesylate16$4,866
Propafenone Hcl ErPropafenone Hcl16$4,454
Icosapent Ethyl19$4,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$148$761,202751 claims
Johnson & JohnsonXarelto$56$205,612181 claims
NovartisEntresto$50$148,349145 claims
Boehringer IngelheimJardiance, Pradaxa$198$98,943116 claims
AstraZenecaFarxiga, Brilinta$339$57,94181 claims
MerckVerquvo$141$14,95117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →